Bile duct cancer, known medically as cholangiocarcinoma, develops when cells lining the bile ducts grow out of control. Most cases arise from prolonged inflammation or damage to these ducts, which carry digestive fluid from the liver to the small intestine. The specific trigger varies widely depending on geography, genetics, and underlying health conditions, and in many cases no single cause is identified. But several well-established risk factors significantly raise the odds.
Chronic Bile Duct Inflammation
The strongest known risk factor in Western countries is primary sclerosing cholangitis (PSC), an immune-mediated condition in which the body attacks its own bile ducts. The resulting long-term inflammation causes scarring and tissue damage that accumulates over years. This cycle of injury and repair eventually corrupts the DNA in bile duct cells, pushing them toward uncontrolled growth. PSC carries a significant lifetime risk of bile duct and gallbladder cancer, and people diagnosed with it are typically monitored with annual imaging.
Chronic bile duct stones (hepatolithiasis) create a similar pattern of ongoing irritation. Stones physically scrape the duct lining, trigger inflammation, and keep the tissue in a constant state of repair. Between 3% and 10% of patients with hepatolithiasis eventually develop bile duct cancer, though exactly why some patients progress and others don’t remains unclear.
Liver Fluke Infections
In East Asia, Southeast Asia, and parts of Eastern Europe, parasitic liver flukes are a leading cause of bile duct cancer. The species most commonly involved are ingested through raw or undercooked freshwater fish. Once inside the body, the flukes take up residence in the bile ducts, where they latch onto the duct lining with oral and ventral suckers, physically tearing the tissue even early in infection.
The damage goes well beyond mechanical injury. The flukes secrete metabolic byproducts that are directly toxic to bile duct cells. At the same time, the immune system floods the area with inflammatory molecules and oxygen radicals that damage DNA. One of those molecules, nitric oxide, is especially dangerous: it not only mutates DNA but also blocks the cell’s ability to repair itself and suppresses the natural self-destruct mechanism that normally eliminates damaged cells. The result is a population of bile duct cells with accumulating genetic errors and no safety net to stop them from becoming cancerous.
In regions where these infections are common, large-scale screening programs use stool tests for fluke eggs alongside abdominal ultrasound to catch early signs of disease.
Congenital Bile Duct Cysts
Some people are born with abnormal dilations of the bile ducts, called choledochal cysts. These structural abnormalities create pockets where bile pools and stagnates, leading to chronic irritation of the duct lining. A meta-analysis of 18 studies covering nearly 3,000 patients found that roughly 11% developed a malignancy. The risk was concentrated almost entirely in two specific cyst types: 99% of the cancers that developed during follow-up occurred in patients with type I or type IV malformations.
Treatment matters significantly. Patients who had their cysts drained but not removed were nearly four times more likely to develop bile duct cancer compared to those who had the cyst completely excised. This is why surgical removal of the cyst, rather than simple drainage, is the standard approach.
Chemical and Occupational Exposures
Certain industrial chemicals are directly linked to bile duct cancer. The clearest modern example comes from a cluster of cases at a Japanese printing company, where workers developed cholangiocarcinoma after years of exposure to high concentrations of 1,2-dichloropropane (1,2-DCP), a solvent used in ink cleaning agents. Workplace air measurements showed concentrations ranging from 60 to 210 parts per million, far above safe thresholds. The International Agency for Research on Cancer subsequently reclassified 1,2-DCP as a confirmed human carcinogen.
Dichloromethane, another solvent the workers were exposed to, was upgraded to “probably carcinogenic to humans” based on the same evidence. A historical example involves Thorotrast, a radioactive contrast agent used in medical imaging in Japan during the 1930s and 1940s, which was later found to cause bile duct cancer decades after exposure.
Genetic Mutations
Bile duct cancer cells often carry specific genetic alterations, and the pattern depends on where the tumor grows. In cancers that form inside the liver (intrahepatic cholangiocarcinoma), two mutations appear frequently. One involves a gene that controls cell growth signals and is found in 10% to 15% of cases. The other affects a metabolic enzyme and appears in 10% to 30% of intrahepatic tumors but is much less common (around 7%) in cancers of the bile ducts outside the liver.
These mutations are not typically inherited. They develop over a person’s lifetime, likely driven by the same inflammation and DNA damage described above. Their importance lies mainly in treatment: tumors carrying these specific mutations can sometimes be targeted with precision therapies that wouldn’t work on other forms of the disease.
Other Contributing Factors
Several additional conditions raise bile duct cancer risk, though to a lesser degree. Cirrhosis from any cause (alcohol, hepatitis B or C, fatty liver disease) increases the likelihood, as does chronic infection with hepatitis B or C even without cirrhosis. Obesity and diabetes have both been associated with higher rates in large population studies. Heavy alcohol use adds to the picture, likely through its contribution to liver inflammation and scarring.
Age is a factor as well. Bile duct cancer is rare before age 50 and peaks in the 70s and 80s. In the United States, the combined rate of new liver and intrahepatic bile duct cancer cases is 9.5 per 100,000 people per year, though bile duct cancer alone accounts for a fraction of that figure.
Why Many Cases Have No Clear Cause
Despite the well-defined risk factors above, the majority of people diagnosed with bile duct cancer in Western countries have none of them. They don’t have PSC, haven’t been exposed to liver flukes, and weren’t born with bile duct cysts. In these cases, the cancer likely results from a combination of low-level genetic susceptibility, environmental exposures that haven’t been identified, and the kind of random DNA copying errors that accumulate with age. This makes bile duct cancer difficult to prevent and, because symptoms often don’t appear until the disease is advanced, difficult to catch early in people who aren’t already being monitored for a known risk factor.